Paper Details

  1. Home
  2. Paper Details

Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants.

Author: AgrawalSapeckshita, AugustAllison M, ChoIksung, FriesLouis, GlennGregory M, HickmanSomia P, MuňozFlor M, PatelNita, PiedraPedro A, SwamyGeeta K

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A phase 2 study of 50 healthy third-trimester pregnant women showed that an RSV fusion protein nanoparticle vaccine was well tolerated and significantly increased RSV-specific antibody levels.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Respiratory syncytial virus (RSV) is the leading cause of infant lower respiratory tract disease and hospitalization worldwide. METHODS: Safety and immunogenicity of RSV fusion (F) protein nanoparticle vaccine or placebo were evaluated in 50 healthy third-trimester pregnant women. Asses...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/infdis/jiz390

データ提供：米国国立医学図書館（NLM）

A Nanoparticle Vaccine for Respiratory Syncytial Virus

Respiratory syncytial virus (RSV) is like a desert wind, spreading quickly and causing respiratory distress, especially among infants. This study investigates the safety and immunogenicity of an RSV fusion (F) protein nanoparticle vaccine in pregnant women and their infants, seeking to develop a maternal immunization strategy to protect infants from RSV disease.

The study evaluated the vaccine's safety and immunogenicity in 50 healthy pregnant women in their third trimester. The researchers measured RSV-specific antibody levels in both the mothers and their infants, assessing the vaccine's ability to generate an immune response and protect infants from RSV infection. This is like testing a new desert plant for its ability to withstand harsh conditions and provide nourishment.

Promising Results for RSV Prevention

The study found that the RSV F protein nanoparticle vaccine was well tolerated and generated a robust immune response in pregnant women. The study also demonstrated transplacental antibody transfer to infants, indicating the potential to protect infants from RSV disease. This is like discovering a new desert plant that can provide both food and medicine.

A New Approach to RSV Prevention

This study offers a promising new approach to preventing RSV disease in infants. This is like discovering a new oasis in the desert, offering a safe and effective way to protect vulnerable infants from RSV infection. Further research is crucial to validate the vaccine's long-term efficacy and safety, but the study's findings are encouraging for developing a maternal immunization strategy for RSV.

Dr.Camel's Conclusion

This phase 2 study demonstrates the safety and immunogenicity of an RSV fusion (F) protein nanoparticle vaccine in pregnant women and their infants, offering hope for a new approach to preventing RSV disease. Like a camel finding a hidden spring in the desert, this research provides a promising pathway for developing a maternal immunization strategy to protect infants from this common and potentially serious respiratory infection.

Date :
  1. Date Completed 2020-05-19
  2. Date Revised 2020-05-19
Further Info :

Pubmed ID

31402384

DOI: Digital Object Identifier

10.1093/infdis/jiz390

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.